Abstract
Purpose
Cisplatin-induced hearing loss is a common side effect in patients treated with cisplatin-based chemoradiation (CRT) for head and neck squamous cell carcinoma. The extent of hearing loss after concurrent CRT was compared between triweekly (3 × 100 mg/m2) and weekly (7 × 40 mg/m2) cisplatin CRT.
Method
This retrospective cohort study was conducted in the Antoni van Leeuwenhoek Hospital and included 129 patients with cisplatin-based CRT for head and neck cancer (72 treated in the triweekly and 57 in the weekly regimen). Baseline and follow-up pure tone audiometry was conducted to assess hearing loss. Clinically relevant hearing loss was defined as a decline upon treatment of ≥ 10 decibel at a pure tone average 1-2-4 kHz and/or 8-10-12.5 kHz.
Results
The incidence of clinically relevant cisplatin CRT induced hearing loss was 42% in the triweekly versus 19% in the weekly group (p < 0.01). The mean threshold shift at a pure tone average (PTA) 1-2-4 kHz was 9.0 decibel in the triweekly compared to 4.3 decibel in the weekly CRT group (p < 0.01). At PTA 8-10-12.5 kHz, the incidence of clinically relevant hearing loss was 75% in the triweekly compared to 74% in the weekly CRT group (p = 0.87). The mean threshold shift at PTA 8-10-12.5 kHz was 20.2 decibel versus 15.6 decibel, respectively (p = 0.07).
Conclusion
Cisplatin-dose reduction to a weekly cisplatin CRT regimen for head and neck cancer may reduce the incidence of clinically relevant hearing loss at frequencies vital for speech perception.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Cisplatin is a widely used anti-cancer drug in treating numerous types of cancers, including head and neck squamous cell carcinoma (HNSCC). Advanced HNSCC is often treated with (adjuvant) high-dose cisplatin chemoradiation (CRT), i.e., 3 × 100 mg/m2, as adding cisplatin to RT leads to improved survival rates in these patients compared to radiotherapy alone [1,2,3]. However, high-dose cisplatin may cause considerable side effects, including acute toxicities such as nausea, stomatitis, myelosuppression [1, 2], nephrotoxicity, neurotoxicity, i.e., peripheral nerve toxicity, and hearing loss [2, 4].
Hearing loss may occur when cisplatin damages various cochlear structures, including the outer and inner hair cells, stria vascularis, and spiral ganglion cells. Several biological processes are involved in developing cisplatin-induced hearing loss (CIHL), amongst others, releasing toxic reactive oxygen species and depleting the cochlea’s protective antioxidants [4,5,6,7,8]. Furthermore, the development of CIHL is influenced by several co-occurring risk factors, including a cochlear radiation dose of more than 30 Gy (Gy) [9, 10], and favorable pre-treatment hearing capacity, as often seen in younger patients [8, 11,12,13,14].
The clinical presentation of CIHL is characterized by symmetric and irreversible sensorineural hearing loss (SNHL) starting at extended high-frequencies and progressing to lower frequencies with continued treatment [4, 5, 15]. However, due to the heterogeneity in treatment schedules and used definitions of ototoxicity in studies conducted so far, it is hard to report the incidence of CIHL precisely [4, 10, 12, 16].
It is widely accepted that a cumulative concurrent cisplatin dose of ≥ 200 mg/m2 is a prerequisite for its anticancer efficacy in advanced HNSCC patients [17, 18]. However, approximately 30% of the patients suffer from cisplatin-related dose-limiting toxicities [19,20,21]. Therefore, an alternative CRT schedule for HNSCC has been designed to reduce toxicity and increase compliance to this intensive treatment regimen. The standard of care triweekly CRT schedule (100 mg/m2 cisplatin, days 1, 22, and 43; further referred to as “triweekly CRT schedule”) was adapted to a weekly CRT schedule (40 mg/m2 cisplatin, weekly during seven consecutive weeks; further referred to as “weekly CRT schedule”). Earlier research showed that the weekly schedule gives less toxicities such as nephrotoxicity and neutropenia [2, 22], however these studies did not elaborate on the difference in hearing loss between both schedules. Therefore, the aim of our study was to compare hearing loss in HNSCC patients treated with weekly and triweekly high-dose cisplatin CRT.
Methods
Study design and subjects
This is a retrospective cohort study with HNSCC patients treated with radiotherapy (five times a week for seven weeks, with a cumulative radiotherapy dose of 70 Gy) and concomitant intravenous cisplatin in a cumulative dose of at least 200 mg/m2. All patients were treated at the Netherlands Cancer Institute. The triweekly CRT group received 100 mg/m2 cisplatin every three weeks (on days 1, 22 and 43). Most of these patients were treated between 1999 and 2004 [23] and 2018 and 2020. The weekly CRT group received a weekly cisplatin dose of 40 mg/m2 (on days 1, 8, 15, 22, 29, 36 and 43) between 2020 and 2023. Due to dose limiting toxicities, some patients did not complete the full planned cisplatin schedule and continued treatment with RT only. We included patients that received a cumulative dose of 200 mg/m2 or more, as this is the minimum cumulative dose of cisplatin needed for increased CRT-related anticancer efficacy. In view of future informed consent for patients we wished to assess treatment-related hearing loss in patients receiving ≥ 200 mg/m2 cisplatin CRT.
Only patients with both baseline and follow-up audiometry were included in the current study. Patients treated with a radiation dose of ≥ 30 Gy at the cochlea were excluded from the analysis, as a RT dose of ≥ 30 Gy to the inner may also cause sensorineural hearing loss [24, 25]. This study was approved by the Institutional Review Board of the Netherlands Cancer Institute (ID IRBd22-261) and executed according to the Declaration of Helsinki.
Audiometric analysis
Pure tone audiometry (0.125–8.0 kHz hearing level (HL)) and extended high-frequency audiometry (8.0–12.5 kHz sound pressure level (SPL)) were performed at baseline and at a median of 6 weeks [Q1-Q3: 5–7 weeks] after treatment. Air conduction (AC) and bone conduction (BC) thresholds (0.5–4 kHz HL) were measured in a sound-proof booth using the Decos Audiology Workstation. If BC thresholds were ≥ 10 dB better than AC thresholds on 0.5, 1, 2, or 4 kHz, BC thresholds were used. In case the AC threshold in extended high-frequency was missing on 8.0 kHz SPL, thresholds were imputed by taking the threshold at 8 kHz HL from pure tone audiometry and adding 13 dB, taking the reference equivalent threshold sound pressure level for 8 kHz as defined in ISO 389-1 [26]. If a patient’s hearing threshold was beyond the audiometer’s maximum output at the follow-up measurement and therefore not testable, this threshold was computed by adding 10 dB to the maximum measurable threshold (i.e., 110 + 10 = 120 dB, depending on the settings of the audiometer).
Two Pure Tone Averages (PTA’s) were calculated. The first PTA is the mean threshold (dB HL) of the frequencies 1, 2, and 4 kHz HL (PTA 1-2-4 kHz), as these frequencies are closely related to speech perception. The other PTA at frequencies 8, 10, and 12.5 kHz SPL (PTA 8-10-12.5 kHz) represents the perception of high sounds as in music but also enhances speech perception in noise [27, 28]. PTA threshold shifts were calculated as post-treatment hearing threshold minus pre-treatment hearing threshold. Clinically relevant CIHL was defined as a threshold shift of ≥ 10 dB at these PTA’s in at least one ear.
Furthermore, CIHL was graded with three grading scales: the International American Speech-Language-Hearing Association (ASHA) grading scale for hearing loss due to ototoxic drugs [29], the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (based on the threshold shifts up to 8 kHz HL) [30], and the TUNE criteria [31] (Appendix A).
Statistical analysis
Baseline characteristics between the two cisplatin groups were compared using Chi-square, Fisher’s exact, and Mann-Whitney-U tests. Incidence of clinically relevant hearing loss and indication for hearing aids de novo were compared between the two cisplatin groups using a Chi-square test. The scores on the grading scale for ototoxicity were compared between the two groups using a linear-by-linear test. The threshold shifts in hearing after therapy (i.e., the difference between post- and pre-treatment hearing threshold) at PTA1-2–4 kHz HL and PTA 8-10-12.5 kHz SPL were compared between the two cisplatin groups using a random intercept linear mixed model. The outcome was expressed per ear, as audiometry data was available for both ears, and nested at patient level. Univariable models were run separately for all PTAs with cisplatin schedule and each of the following covariates: baseline age, sex, cumulative cisplatin dose/m2, cochlear radiation dose, and baseline hearing level at PTA 1-2-4 kHz. If the p-value for a covariate was < 0.1, this covariate was added to the multivariable model with cisplatin schedule. Additionally, interaction terms between significant values in the univariable analysis were added to multivariable models and retained if significant. Data analysis was performed using IBM SPSS Statistics 27. A p-value of < 0.05 was considered statistically significant.
Results
Subjects
One hundred ten patients were treated in the triweekly CRT cohort. Thirty-eight patients were excluded because of baseline audiometry missing (n = 5), follow-up audiometry missing (n = 16), dose-limiting toxicity leading to a cumulative cisplatin dose < 200 mg/m2 (n = 2), and cochlear radiation dose ≥ 30 Gy (n = 15), resulting in 72 evaluable patients. Sixty-nine patients were treated with the weekly CRT schedule. Twelve of them were excluded from the analysis because of baseline audiometry missing (n = 3), follow-up audiometry missing (n = 1), dose-limiting toxicity leading to a cumulative cisplatin dose < 200 mg/m2 (n = 5), and radiotherapy dose on cochlea ≥ 30 Gy (n = 3), resulting in 57 evaluable patients.
The baseline characteristics of both treatment groups are shown in Table 1. Patients in the triweekly CRT group were relatively younger (56.2 versus 60.7 years old, p < 0.01). In the weekly CRT group, 65% of all patients were treated for oropharyngeal cancer compared to 36% in the triweekly CRT group. The mean cochlear radiotherapy dose was higher in the triweekly CRT group, namely 14.2 Gy versus 8.1 Gy (p < 0.01).
Audiometry results
The audiometric data of all patients in both cohorts is presented in Fig. 1; Table 2. The mean threshold shift at PTA 1-2-4 kHz was 9.0 (± 9.9) dB in the triweekly CRT group and 4.3 (± 8.2) dB in the weekly CRT group (p < 0.01). The mean threshold shift at PTA 8-10-12.5 kHz was 20.2 (± 16.4) dB in the triweekly CRT group and 15.6 (± 14.0) dB in the weekly CRT group (p = 0.07). At the frequencies of 1-2-4 kHz, we observed clinically relevant CIHL, defined as a threshold shift of 10 dB or more, in 31 out of 72 patients (42%) from the triweekly CRT group and 11 out of 57 patients (19%) from the weekly CRT group (p < 0.01). At frequencies of 8-10-12.5 kHz, clinically relevant CIHL was observed in 54 out of 72 patients (75%) from the triweekly CRT group and 42 out of 57 patients (74%) from the weekly CRT group (p = 0.87). Significantly higher grading scale scores were observed in the triweekly CRT schedule compared to the weekly CRT schedule on both the CTCAE and TUNE (both p < 0.01). However, hearing loss, as defined by the ASHA criteria, was not significantly different between both groups (p = 0.81). Furthermore, more patients in the triweekly CRT group had an indication for hearing aids de novo after treatment compared to the weekly CRT schedule (36% versus 14%, p < 0.01).
Linear mixed model
Results of univariable and multivariable linear mixed model analyses are presented in Tables 3 and 4. The threshold shift in hearing after therapy at PTA 1-2-4 kHz HL was significantly higher by 3.5 dB in the triweekly CRT group compared to the weekly CRT group (estimate 3.55, 95% CI 0.15–6.95, p = 0.04) after adjustment for radiotherapy dose to the cochlea, age and baseline hearing level at PTA 1-2-4 kHz. The threshold shift was significantly higher with higher cochlear radiation dose (estimate 0.28, 95% CI 0.12–0.44, p < 0.01). However, the difference in threshold shift in hearing after therapy at PTA 8-10-12.5 kHz HL was smaller and not significant between the two cisplatin CRT schedules (estimate – 0.50, 95% CI -4.71–5.71, p = 0.85) after adjustment for baseline age, radiotherapy dose to the cochlea and baseline hearing level at PTA 1-2-4 kHz. The threshold shift at PTA 8-10-12,5 kHz was significantly smaller in older patients (estimate – -0.36., 95% CI -0.64 – -0.09, p = 0.01) and in patients with worse baseline hearing level at PTA 1-2-4 kHz (estimate – -0.21, 95% CI -0.39 – -0.05, p = 0.01). The threshold shift at PTA 8-10-12,5 kHz was significantly higher with higher cochlear radiation dose (estimate 0.33, 95% CI 0.08–0.58, p = 0.01). No significant interactions were found between the variables used in the multivariable model.
Discussion
Although the main goal of anticancer therapy remains to achieve better survival and loco-regional control, improving post-treatment quality of life by reducing treatment-related toxicity has become increasingly important [11, 32]. In HNSCC, weekly cisplatin CRT (7 cycles of 40 mg/m2 cisplatin during seven consecutive weeks) achieves similar survival rates when compared to triweekly CRT (3 cycles of 100 mg/m2 cisplatin every three weeks) [2, 22]. Also, it is accompanied by less cisplatin toxicities such as nephrotoxicity, neutropenia, and electrolyte disturbances [2, 22]. The objective of this study was to assess whether adopting a weekly CRT schedule reduces CIHL.
The implementation of weekly CRT may contribute to preserving hearing capacity and improving quality of life [11, 32]. In our research, the incidence of clinically relevant hearing loss of ≥ 10 dB at PTA 1-2-4 kHz, representing the perception of speech in noise, was found significantly higher in the triweekly CRT group compared to the weekly CRT group (42% versus 19%, p < 0.01), in agreement with previous studies [2, 33]. The 23%-point difference in the incidence, the marked difference in hearing-aid candidacy (36% versus 14%), CTCAE criteria (p < 0.01) and TUNE criteria (p < 0.01) indicate benefit of a weekly cisplatin regimen over a triweekly cisplatin regimen with respect to CRT-induced hearing loss in HNSCC patients. Consequently, a weekly cisplatin regimen might reduce adverse effects commonly observed in HNSCC patients’ health-related quality of life, including social isolation, anxiety, and depression [32, 34]. Careful interpretation of our data is warranted in view of the retrospective nature of our research. A limitation of this retrospective design was that the lack of speech audiometry in most patients, which would have provided valuable extra information about speech processing capacity prior and after CRT. However, a detailed description of data was, available for all patients, including audiometric hearing thresholds up to 12.5 kHz SPL, the cochlear radiation dose per ear, and the gradation of hearing loss as defined by different grading scales. Therefore, for monitoring CIHL, we recommend standard and extended high-frequency pure tone audiometry in all patients treated with high-dose CRT, at least before the start of treatment and approximately two to three months after the last CRT.
We found a significant association between cochlear radiation dose and CIHL, in agreement with previous studies that found a cochlear radiation dose ≥ 30 Gy to cause clinically relevant sensorineural hearing loss of ≥ 10 dB [9, 24]. Other literature advises to limit the radiation dose to the cochlea to ≤ 35 Gy [25, 35], however we chose to use the most strict cut-off value. The triweekly CRT group, mainly treated between 1999 and 2004, received a higher mean cochlear radiation dose, attributed to a difference in radiation techniques and planning in the years 1999–2004 when compared to more recently treated patients in both the weekly and triweekly CRT schedule (16.1 Gy versus 8.4 Gy). Despite the limitation of this time difference and difference in radiation technique, after correcting for the mean cochlear radiation dose in our multivariable analysis, significantly more hearing loss at PTA 1-2-4 was found in the triweekly compared to the weekly CRT group. Also, we found no significant difference in CIHL between patients in the triweekly groups treated between 1999 and 2004 and 2018–2020 on PTAs 1-2-4 (p = 0.08) and 8-10-12,5 (p = 0.36). Therefore we believe that it is justified to evaluate all triweekly patients as one cohort, regardless of the difference in treatment period.
Even though weekly CRT may decrease the incidence of cisplatin-CRT induced hearing loss, there is still a need for an otoprotectant in both treatment regimens. Recently, both systemic and topical (transtympanic) approaches have been studied to reduce CIHL with varying successes [11, 13, 36, 37]. Antioxidants are probably the most encouraging otoprotective agents, as they can neutralize the toxic formation of reactive oxygen species by cisplatin. Interestingly, the antioxidant sodium-thiosulphate (STS) can also inactivate cisplatin. When STS is injected into the middle ear (transtympanically), it may locally inactivate cisplatin without interfering with its systemic anticancer effect. In a recent phase I trial, this method was safe and feasible [38]. Its efficacy is currently studied further in a multicenter phase 3 randomized controlled setting (CTIS 2023-503313-30-01). The current study shows that patients treated in both schedules are still prone to develop clinically relevant CIHL. Therefore, HNSCC patients treated in both the triweekly and the weekly CRT schedule are eligible to participate in our phase 3 trial regarding the efficacy of transtympanic STS against CIHL.
In conclusion, hearing capacity seems to be relatively preserved after treatment with a weekly cisplatin CRT regimen (7 cycles of 40 mg/m2 cisplatin during seven consecutive weeks) when compared to triweekly cisplatin CRT regimen (3 cycles of 100 mg/m2 cisplatin every three weeks) for HNSCC. However, both treatment schedules induce clinically relevant CIHL at extended high-frequencies, which impairs the quality of higher sounds (e.g., for music) and speech perception in noise [27, 28]. Currently a multicenter phase 3 study to evaluate the efficacy of transtympanic STS against CIHL is underway. Ultimately, these efforts should reduce CIHL and thereby increase the quality of life in HNSCC patients and survivors.
Appendix A
Data availability
Research data are stored in an institutional repository and can be shared upon request to the corresponding author and after ethical clearance of the NKI Institutional Review Board.
References
Forastiere AA, Zhang Q, Weber RS et al (2013) Long-term results of rtog 91 – 11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31(7):845–852. https://doi.org/10.1200/JCO.2012.43.6097
Bauml JM, Vinnakota R, Anna Park YH et al (2019) Cisplatin every 3 weeks versus weekly with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck. J Natl Cancer Inst 111(5):490–497. https://doi.org/10.1093/jnci/djy133
Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952. https://doi.org/10.1056/NEJMoa032641
Paken J, Govender CD, Pillay M, Sewram V (2016) Cisplatin-associated ototoxicity: a review for the health professional. J Toxicol 2016:1809394. https://doi.org/10.1155/2016/1809394
Callejo A, Sedo-Cabezon L, Juan ID, Llorens J (2015) Cisplatin-induced ototoxicity: effects, mechanisms and protection strategies. Toxics 3(3):268–293. https://doi.org/10.3390/toxics3030268
Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V (2007) Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 226(1–2):157–167. https://doi.org/10.1016/j.heares.2006.09.015
Karasawa T, Steyger PS (2015) An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett 237(3):219–227. https://doi.org/10.1016/j.toxlet.2015.06.012
Lanvers-Kaminsky C, Zehnhoff-Dinnesen AA, Parfitt R, Ciarimboli G (2017) Drug-induced ototoxicity: mechanisms, pharmacogenetics, and protective strategies. Clin Pharmacol Ther 101(4):491–500. https://doi.org/10.1002/cpt.603
Jereczek-Fossa BA, Zarowski A, Milani F, Orecchia R (2003) Radiotherapy-induced ear toxicity. Cancer Treat Rev 29:417–430
Schmitt NC, Page BR (2018) Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients. Int J Audiol 57(sup4):S49–S54. https://doi.org/10.1080/14992027.2017.1353710
Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM (2022) Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: a systematic review and meta-analysis. Cancer Epidemiol 79:102203. https://doi.org/10.1016/j.canep.2022.102203
Theunissen EA, Bosma SC, Zuur CL et al (2015) Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature. Head Neck 37(2):281–292. https://doi.org/10.1002/hed.23551
Rybak LP, Mukherjea D, Ramkumar V (2019) Mechanisms of cisplatin-induced ototoxicity and prevention. Semin Hear 40(2):197–204. https://doi.org/10.1055/s-0039-1684048
Zuur CL, Simis YJ, Lansdaal PE et al (2006) Audiometric patterns in ototoxicity of intra-arterial cisplatin chemoradiation in patients with locally advanced head and neck cancer. Audiol Neurootol 11(5):318–330. https://doi.org/10.1159/000095818
Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD (2016) Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol 35:2712–2720
Trendowski MR, El Charif O, Dinh PC Jr., Travis LB, Dolan ME (2018) Genetic and modifiable risk factors contributing to cisplatin-induced toxicities. Clin Cancer Res. doi: 10.1158/1078 – 0432.CCR-18-2244
Spreafico A, Huang SH, Xu W et al (2016) Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. Eur J Cancer 67:174–182. https://doi.org/10.1016/j.ejca.2016.08.013
Strojan P, Vermorken JB, Beitler JJ et al (2016) Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review. Head Neck 38(Suppl 1):E2151–E2158. https://doi.org/10.1002/hed.24026
Wendrich AW, Swartz JE, Bril SI et al (2017) Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol 71:26–33. https://doi.org/10.1016/j.oraloncology.2017.05.012
Bril SI, Al-Mamgani A, Chargi N et al (2021) The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin. Head Neck 44(1):189–200. https://doi.org/10.1002/hed.26919
Beijer YJ, Koopman M, Terhaard CH, Braunius WW, van Es RJ, de Graeff A (2013) Outcome and toxicity of radiotherapy combined with chemotherapy or cetuximab for head and neck cancer: our experience in one hundred and twenty-five patients. Clin Otolaryngol 38(1):69–74. https://doi.org/10.1111/coa.12002
Helfenstein S, Riesterer O, Meier UR et al (2019) 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis. Radiat Oncol 14(1):32. https://doi.org/10.1186/s13014-019-1235-y
Zuur CL, Simis YJ, Lansdaal PE et al (2007) Ototoxicity in a randomized phase iii trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol 25(24):3759–3765. https://doi.org/10.1200/JCO.2006.08.9540
Landier W (2016) Ototoxicity and cancer therapy. Cancer 122(11):1647–1658. https://doi.org/10.1002/cncr.29779
Bhandare N, Jackson A, Eisbruch A et al (2010) Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys 76(3 Suppl):S50–S57. https://doi.org/10.1016/j.ijrobp.2009.04.096
Iso (1998) 389-1, acoustics - reference zero for the calibration of audiometric equipment
Motlagh Zadeh L, Silbert NH, Sternasty K, Swanepoel W, Hunter LL, Moore DR (2019) Extended high-frequency hearing enhances speech perception in noise. Proc Natl Acad Sci U S A 116(47):23753–23759. https://doi.org/10.1073/pnas.1903315116
Polspoel S, Kramer SE, van Dijk B, Smits C (2022) The importance of extended high-frequency speech information in the recognition of digits, words, and sentences in quiet and noise. Ear Hear 43(3):913–920. https://doi.org/10.1097/aud.0000000000001142
American speech-language-hearing association (asha), guidelines: Audiologic management of individuals receiving cochleotoxic drug therapy. https://wwwashaorg/policy/gl1994-00003/#sec214.
U.S. Department of health and human services: Common terminology criteria for adverse events (ctcae) version 5.0 (2017) https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf
Theunissen EA (2014) A new grading system for ototoxicity in adults. https://doi.org/10.1177/0003489414534010
Chattaraj A, Syed MP, Low CA, Owonikoko TK (2023) Cisplatin-induced ototoxicity: a concise review of the burden, prevention, and interception strategies. JCO Oncol Pract 19(5):278–283. https://doi.org/10.1200/OP.22.00710
Noronha V, Joshi A, Patil VM et al (2018) Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase iii randomized noninferiority trial. J Clin Oncol 36(11):1064–1072. https://doi.org/10.1200/JCO.2017.74.9457
Deal JA, Reed NS, Kravetz AD et al (2019) Incident hearing loss and comorbidity, a longitudinal administrative claims study. JAMA Otolaryngol Head Neck Surg 145:36–43. https://doi.org/10.1001/jamaoto.2018.2876
Apoorva KV, Vijendra Shenoy S, Athiyamaan MS, Kabekkodu S, Kshithi K, Zuturu N (2023) Radiation dose to the cochlea and its association with sensorineural hearing loss in head and neck cancer-a prospective study. Am J Otolaryngol 44(4):103914. https://doi.org/10.1016/j.amjoto.2023.103914
Laurell G (2019) Pharmacological intervention in the field of ototoxicity. HNO 67(6):434–439. https://doi.org/10.1007/s00106-019-0663-1
Guthrie OW, Spankovich C (2023) Emerging and established therapies for chemotherapy-induced ototoxicity. J Cancer Surviv. https://doi.org/10.1007/s11764-022-01317-6
Duinkerken CW, de Weger VA, Dreschler WA et al (2021) Transtympanic sodium thiosulfate for prevention of cisplatin-induced ototoxicity: a randomized clinical trial. Otol Neurotol 42(5):678–685. https://doi.org/10.1097/MAO.0000000000003069
Funding
This manuscript was written without any financial support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The Authors declare that there is no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Burger, A.V.M., Duinkerken, C.W., van Sluis, K.E. et al. Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer. Eur Arch Otorhinolaryngol (2024). https://doi.org/10.1007/s00405-024-08880-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00405-024-08880-x